Bristol Myers, trailing Merck in lung cancer, finally wins FDA OK for immunotherapy combo

The long-sought approval of Opdivo and Yervoy gives Bristol Myers an entry into the competitive first-line lung cancer drug market after years of setbacks.

Bristol Myers, trailing Merck in lung cancer, finally wins FDA OK for immunotherapy combo
The long-sought approval of Opdivo and Yervoy gives Bristol Myers an entry into the competitive first-line lung cancer drug market after years of setbacks.